FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897777663> ?p ?o ?g. }

• W2897777663 endingPage "e255" @default.
• W2897777663 startingPage "e255" @default.
• W2897777663 abstract "Given improvements in systemic therapy, metastatic melanoma to the brain represents a rapidly growing subgroup of advanced melanoma patients, with intracranial disease control being an increasingly important goal. These patients are often treated with stereotactic radiosurgery (SRS) and anti-PD1 therapy, which have independently demonstrated efficacy in improving survival. However, limited data exists regarding the management of brain metastatic melanoma using a combination of such therapies. We performed a single institution retrospective analysis of outcomes of patients with brain metastases of melanoma primary treated with SRS and PDL1 therapy compared to SRS alone. Patients diagnosed with metastatic brain lesions of melanoma primary whose management included one or more courses of SRS between 2011 and 2015 were identified. Patient and treatment characteristics were reviewed, including the types of systemic therapy received. Survival was measured from time of diagnosis of brain metastases to death or last follow-up. Overall survival was compared between patients who received or did not receive PDL1 therapy using Kaplan Meier curves with log-rank testing. Multivariate Cox regression analysis was performed to account for other potentially confounding factors. Rates of post-SRS radionecrosis were also assessed. Fifty-two patients had brain lesions treated with SRS, of which 31 received SRS alone and 21 also received anti-PD1 therapy. There were no significant differences between the two treatment groups with respect to age, number of metastases, or rates of prior CTLA4 or BRAF therapy. Median survival for the combined cohort was 16 months. Median survival was significantly longer in patients receiving SRS+PD1 therapy vs SRS alone, 52 vs 12 months, respectively (p=0.011). Overall survival at 1 year was 86% and 67%, respectively, and at 2 years was 61% and 21%, respectively. A multivariate Cox regression that included age, sex, receipt of craniotomy, prior systemic therapy, number of brain metastases, and extracranial disease control revealed that PDL1 therapy remained an independent predictor of survival (p=0.026). Receipt of craniotomy and extracranial disease control were also statistically favorable prognostic factors (p=0.038 and p=0.037, respectively). Radiographic radionecrosis was observed in three (5.7%) patients, of which two were in patients receiving both SRS+PDL1 therapy. The survival of patients with melanoma brain metastases was significantly improved with the addition of the PD-1 antibody to SRS, with benefit remaining on multivariate analysis. The combination of these therapies appears to be safe and offers durable benefit to this growing subset of patients with advanced melanoma." @default.
• W2897777663 created "2018-10-26" @default.
• W2897777663 creator A5017237984 @default.
• W2897777663 creator A5036408428 @default.
• W2897777663 creator A5036760030 @default.
• W2897777663 creator A5075849476 @default.
• W2897777663 creator A5078198020 @default.
• W2897777663 creator A5078665811 @default.
• W2897777663 creator A5079717318 @default.
• W2897777663 creator A5091859107 @default.
• W2897777663 date "2018-11-01" @default.
• W2897777663 modified "2023-09-26" @default.
• W2897777663 title "Outcomes for Advanced Melanoma with Brain Metastases Treated with Stereotactic Radiosurgery (SRS) with and without Anti-PD1/PDL1 Therapy" @default.
• W2897777663 doi "https://doi.org/10.1016/j.ijrobp.2018.07.840" @default.
• W2897777663 hasPublicationYear "2018" @default.
• W2897777663 type Work @default.
• W2897777663 sameAs 2897777663 @default.
• W2897777663 citedByCount "0" @default.
• W2897777663 crossrefType "journal-article" @default.
• W2897777663 hasAuthorship W2897777663A5017237984 @default.
• W2897777663 hasAuthorship W2897777663A5036408428 @default.
• W2897777663 hasAuthorship W2897777663A5036760030 @default.
• W2897777663 hasAuthorship W2897777663A5075849476 @default.
• W2897777663 hasAuthorship W2897777663A5078198020 @default.
• W2897777663 hasAuthorship W2897777663A5078665811 @default.
• W2897777663 hasAuthorship W2897777663A5079717318 @default.
• W2897777663 hasAuthorship W2897777663A5091859107 @default.
• W2897777663 hasConcept C10515644 @default.
• W2897777663 hasConcept C121608353 @default.
• W2897777663 hasConcept C126322002 @default.
• W2897777663 hasConcept C141071460 @default.
• W2897777663 hasConcept C143998085 @default.
• W2897777663 hasConcept C167135981 @default.
• W2897777663 hasConcept C185926286 @default.
• W2897777663 hasConcept C2777658100 @default.
• W2897777663 hasConcept C2778164965 @default.
• W2897777663 hasConcept C2779013556 @default.
• W2897777663 hasConcept C2780387249 @default.
• W2897777663 hasConcept C38180746 @default.
• W2897777663 hasConcept C502942594 @default.
• W2897777663 hasConcept C50382708 @default.
• W2897777663 hasConcept C509974204 @default.
• W2897777663 hasConcept C530470458 @default.
• W2897777663 hasConcept C71924100 @default.
• W2897777663 hasConcept C72563966 @default.
• W2897777663 hasConceptScore W2897777663C10515644 @default.
• W2897777663 hasConceptScore W2897777663C121608353 @default.
• W2897777663 hasConceptScore W2897777663C126322002 @default.
• W2897777663 hasConceptScore W2897777663C141071460 @default.
• W2897777663 hasConceptScore W2897777663C143998085 @default.
• W2897777663 hasConceptScore W2897777663C167135981 @default.
• W2897777663 hasConceptScore W2897777663C185926286 @default.
• W2897777663 hasConceptScore W2897777663C2777658100 @default.
• W2897777663 hasConceptScore W2897777663C2778164965 @default.
• W2897777663 hasConceptScore W2897777663C2779013556 @default.
• W2897777663 hasConceptScore W2897777663C2780387249 @default.
• W2897777663 hasConceptScore W2897777663C38180746 @default.
• W2897777663 hasConceptScore W2897777663C502942594 @default.
• W2897777663 hasConceptScore W2897777663C50382708 @default.
• W2897777663 hasConceptScore W2897777663C509974204 @default.
• W2897777663 hasConceptScore W2897777663C530470458 @default.
• W2897777663 hasConceptScore W2897777663C71924100 @default.
• W2897777663 hasConceptScore W2897777663C72563966 @default.
• W2897777663 hasIssue "3" @default.
• W2897777663 hasLocation W28977776631 @default.
• W2897777663 hasOpenAccess W2897777663 @default.
• W2897777663 hasPrimaryLocation W28977776631 @default.
• W2897777663 hasRelatedWork W1998730019 @default.
• W2897777663 hasRelatedWork W2054419658 @default.
• W2897777663 hasRelatedWork W2066530402 @default.
• W2897777663 hasRelatedWork W2376493575 @default.
• W2897777663 hasRelatedWork W2393302019 @default.
• W2897777663 hasRelatedWork W2587755700 @default.
• W2897777663 hasRelatedWork W2747510197 @default.
• W2897777663 hasRelatedWork W2778018952 @default.
• W2897777663 hasRelatedWork W2800706802 @default.
• W2897777663 hasRelatedWork W626724044 @default.
• W2897777663 hasVolume "102" @default.
• W2897777663 isParatext "false" @default.
• W2897777663 isRetracted "false" @default.
• W2897777663 magId "2897777663" @default.
• W2897777663 workType "article" @default.